- [email protected]
- 24/7 Support Available
What is CJC-1295 no DAC + Ipamorelin?
This research blend combines CJC-1295 (without DAC) and Ipamorelin, two complementary peptides that act synergistically on different receptors to produce a robust and physiologically-patterned growth hormone pulse. CJC-1295 no DAC is a modified GHRH tetrasubstituted analog, while Ipamorelin is a selective GHRP-derived ghrelin mimetic.
Blend Components
| CJC-1295 no DAC (5mg) | Modified GHRH analog (MOD GRF 1-29) that stimulates pituitary GHRH receptors with a short half-life, preserving physiological GH pulsatility. |
| Ipamorelin (5mg) | Selective GHRP/ghrelin mimetic that activates GHS-R1a receptors, amplifying GH release without significant cortisol or prolactin elevation. |
CJC-1295 no DAC + Ipamorelin Research
1. Synergistic GH Release
Preclinical and clinical data demonstrate that GHRH + GHRP combinations produce significantly greater GH pulses than either peptide alone, due to complementary receptor activation and pituitary sensitisation.
2. Selective GH Secretagogue Profile
Ipamorelin’s selectivity for GHS-R1a means the combination does not significantly elevate cortisol or ACTH, making it a cleaner research tool compared to first-generation GHRPs like GHRP-6.
3. Body Composition Research
Animal models show this combination promotes lean mass accrual, fat oxidation, and improvements in sleep architecture associated with GH pulsatility.
Future Research
Research is ongoing into optimal dosing intervals, aging applications, and combination protocols with IGF-1 and other peptides.
Resources
- Sigalos JT, Pastuszak AW. – The Safety and Efficacy of Growth Hormone Secretagogues. Sex Med Rev, 2018.
- Raun K, et al. – Ipamorelin, the first selective growth hormone secretagogue. Eur J Endocrinol, 1998.
Reviews
There are no reviews yet.